Foamix Pharmaceuticals has entered into a long term contract manufacturing and supply agreement with ASM Aerosol-Service for the company’s recently approved AMZEEQ (minocycline) topical foam, 4% for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older and for its product candidate FMX103 (minocycline) topical foam, 1.5% for the potential treatment of moderate to severe papulopustular rosacea in adults. ASM will manufacture and supply AMZEEQ and FMX103 at its facility in Möhlin, Switzerland.
 
“This agreement represents another milestone in our overall strategy to bring AMZEEQ to market in January 2020 and to commercialize FMX103 when and if approved by the FDA,” said David Domzalski, chief executive officer, Foamix. “Entering into a manufacturing contract with ASM is a critical step in securing our supply chain, which we believe will ensure the availability of supply once we launch AMZEEQ and, if approved, FMX103.”
 
With the receipt of FDA approval of AMZEEQ, formerly known as FMX101, and entry into the contract manufacturing and supply agreement with ASM, the company now has access to up to an additional $20 million of financing under its existing credit agreement with Perceptive and OrbiMed to fund the commercial launches of AMZEEQ and, pending FDA approval, FMX103.